Mayo, thanks for the insight. If time permits at the meeting this week can you bring up Schizophrenia. Mgt should have already had a meeting with FDA on this I would think. We need to get this trial started IMO regardless of what is happening with EMA. This would be relatively short term trial.
Don't confirm what you believe, ask your good questions. I've asked IR to allot time for a full Q&A, particularly for you, and hope others do the same.
Jesse--"The reasons I assessed approval previously still stand and are to be presented"--thanks for your detailed explanation !!! Now looking forward to the Tuesday. CC !!
Market Data 
Markets 
AI
